Advancing Simulation of 6-Mercaptopurine and Methotrexate Therapy by Using Synthetic Childhood Acute Lymphoblastic Leukemia Patients

6-Mercaptopurine (6-MP) and Methotrexate (MTX) are two drugs used for maintenance therapy of Childhood Acute Lymphoblastic Leukemia (ALL). In terms of therapy, optimum drug dosing for 6-MP and MTX are important for sustainable antileukemic activity without high myelosuppression. Because of this, the literature has efforts on modeling pharmacokinetics (PK) and pharmacodynamics (PD) of both drugs. Beyond modeling, additional analyses should always be done to see how defined models respond to different patient parameters and produce further insights. However, it is an open challenge to work on real patient data, which can be insufficient to produce meaningful findings for validating the models. In this context, the objective of this study is to develop a platform, which can produce synthetic patients and simulate the maintenance therapy on them. In this way, it is believed that a wider perspective can be achieved to understand the potential of the models and produce realistic data for potential use in advanced technologies such as Artificial Intelligence.